JPWO2023116607A5 - - Google Patents
Info
- Publication number
- JPWO2023116607A5 JPWO2023116607A5 JP2024533904A JP2024533904A JPWO2023116607A5 JP WO2023116607 A5 JPWO2023116607 A5 JP WO2023116607A5 JP 2024533904 A JP2024533904 A JP 2024533904A JP 2024533904 A JP2024533904 A JP 2024533904A JP WO2023116607 A5 JPWO2023116607 A5 JP WO2023116607A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleotide sequence
- nucleotide
- seq
- sirna
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111575800 | 2021-12-21 | ||
| CN202111575800.2 | 2021-12-21 | ||
| PCT/CN2022/139942 WO2023116607A1 (zh) | 2021-12-21 | 2022-12-19 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024546667A JP2024546667A (ja) | 2024-12-26 |
| JPWO2023116607A5 true JPWO2023116607A5 (https=) | 2025-12-24 |
| JP2024546667A5 JP2024546667A5 (https=) | 2025-12-24 |
Family
ID=86901326
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024533904A Pending JP2024546667A (ja) | 2021-12-21 | 2022-12-19 | 核酸、当該核酸を含む組成物及び複合体並びに調製方法と使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250057870A1 (https=) |
| EP (1) | EP4455284A1 (https=) |
| JP (1) | JP2024546667A (https=) |
| KR (1) | KR20240117104A (https=) |
| CN (1) | CN118202049A (https=) |
| AU (1) | AU2022422864A1 (https=) |
| CA (1) | CA3242059A1 (https=) |
| WO (1) | WO2023116607A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020280438B2 (en) | 2019-05-22 | 2025-03-06 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| JP7610268B2 (ja) | 2019-05-22 | 2025-01-08 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| WO2020233680A1 (zh) | 2019-05-22 | 2020-11-26 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| EP3978609A4 (en) | 2019-05-24 | 2024-02-07 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| CN121780524A (zh) * | 2024-08-02 | 2026-04-03 | 北京尧景基因技术有限公司 | 抑制MAPT基因表达的siRNA及其缀合物和应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009143371A2 (en) * | 2008-05-21 | 2009-11-26 | Intradigm Corporation | COMPOSITIONS COMPRISING mTOR SIRNA AND METHODS OF USE THEREOF |
| WO2010064851A2 (ko) * | 2008-12-02 | 2010-06-10 | 울산대학교 산학협력단 | 종간 교차활성을 지닌 ｍＴＯＲ을 표적으로 하는 ｓｉＲＮＡ, 이를 포함하는 재조합벡터 및 이를 함유하는 약학조성물 |
| US20120136073A1 (en) | 2010-11-15 | 2012-05-31 | Life Technologies Corporation | Amine-Containing Transfection Reagents and methods for making and using same |
| WO2017151732A1 (en) * | 2016-03-02 | 2017-09-08 | Beth Israel Deaconess Medical Center Technology Venture Office, Br2 | Therapeutic targets for lin-28-expressing cancers |
| AU2018216509B2 (en) * | 2017-01-31 | 2024-02-29 | Curigin Co.,Ltd. | Nucleic acid simultaneously inhibiting expression of mTOR gene and STAT3 gene |
| TN2019000308A1 (en) | 2017-07-06 | 2021-05-07 | Arrowhead Pharmaceuticals Inc | RNAi AGENTS FOR INHIBITING EXPRESSION OF ALPHA-ENaC AND METHODS OF USE |
| WO2019105437A1 (zh) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| EP3732185B1 (en) | 2017-12-29 | 2025-02-26 | Suzhou Ribo Life Science Co., Ltd. | Conjugates and preparation and use thereof |
| WO2019217459A1 (en) | 2018-05-07 | 2019-11-14 | Alnylam Pharmaceuticals, Inc. | Extrahepatic delivery |
| WO2020018461A1 (en) * | 2018-07-16 | 2020-01-23 | The University Of Virginia Patent Foundation | Compositions and methods of diagnosis and treatment for neurological diseases |
| CN112423795A (zh) * | 2018-12-28 | 2021-02-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
-
2022
- 2022-12-19 AU AU2022422864A patent/AU2022422864A1/en active Pending
- 2022-12-19 EP EP22909920.5A patent/EP4455284A1/en active Pending
- 2022-12-19 CN CN202280068763.2A patent/CN118202049A/zh active Pending
- 2022-12-19 KR KR1020247021150A patent/KR20240117104A/ko active Pending
- 2022-12-19 JP JP2024533904A patent/JP2024546667A/ja active Pending
- 2022-12-19 US US18/722,280 patent/US20250057870A1/en active Pending
- 2022-12-19 WO PCT/CN2022/139942 patent/WO2023116607A1/zh not_active Ceased
- 2022-12-19 CA CA3242059A patent/CA3242059A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7249080B2 (ja) | 可逆的に修飾されたオリゴヌクレオチドを含む組成物及びその使用 | |
| JP7798836B2 (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| JP2021113232A (ja) | ペプチドオリゴヌクレオチドコンジュゲート | |
| JP7748500B2 (ja) | トリループを含む二本鎖核酸インヒビター分子 | |
| JP7515400B2 (ja) | Ｂ型肝炎ウイルス感染を治療するためのｆｕｂｐ１阻害剤の使用 | |
| JP2022501059A5 (https=) | ||
| JP2009532044A5 (https=) | ||
| TW202220695A (zh) | 寡核苷酸之全身遞送 | |
| CN111448317B (zh) | 包含二硫代磷酸酯核苷间键的缺口聚物寡核苷酸 | |
| WO2021049504A1 (ja) | 肝臓送達用ＧａｌＮＡｃ－オリゴヌクレオチドコンジュゲートおよび製造方法 | |
| CN111448316B (zh) | 新的硫代亚磷酰胺 | |
| KR20250125967A (ko) | 진보된 rna 표적화 (arnatar) | |
| JPWO2020063198A5 (https=) | ||
| JPWO2023116607A5 (https=) | ||
| CA3136676A1 (en) | Double-stranded nucleic acid inhibitor molecules with shortened sense strands | |
| US20240336920A1 (en) | Threose nucleic acid antisense oligonucleotides and methods thereof | |
| JP7813254B2 (ja) | Ｆｕｂｐ１発現を調節するための増強されたオリゴヌクレオチド | |
| TW202309286A (zh) | 作為新穎基因靜默技術的非對稱短雙股ｄｎａ及其應用 | |
| TW202313977A (zh) | 作為新穎基因靜默技術的短雙股ｄｎａ及其應用 | |
| JP2022521510A (ja) | ホスホノアセテートギャップマー型オリゴヌクレオチド | |
| JPWO2020146521A5 (https=) | ||
| JPWO2023109940A5 (https=) | ||
| JPWO2023098908A5 (https=) | ||
| JPWO2022250050A5 (https=) | ||
| JPWO2023284559A5 (https=) |